Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis
Objectives: Methotrexate is successfully used in the treatment of arthritis but little is known about its effects on extra-articular manifestations of rheumatoid arthritis. We focused this work on the incidence and clinical course of extra-articular manifestations during long-term treatment with met...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 1993
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/27919
- Acceso en línea:
- https://repository.urosario.edu.co/handle/10336/27919
- Palabra clave:
- Methotrexate
Vasculitis
- Rights
- License
- Bloqueado (Texto referencial)
id |
EDOCUR2_d131ac3f2ae4c0de2f076d14545ac9fb |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/27919 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
spelling |
19474778600e8938956-af14-46bd-9749-62565a90def1363a398e-e9c8-42e8-bf3b-ad30173847266fdc324f-d229-4e2c-8776-e4dbea7e7b64799436366002020-08-19T14:44:38Z2020-08-19T14:44:38Z1993Objectives: Methotrexate is successfully used in the treatment of arthritis but little is known about its effects on extra-articular manifestations of rheumatoid arthritis. We focused this work on the incidence and clinical course of extra-articular manifestations during long-term treatment with methotrexate.Methods: The effect of methotrexate on extra-articular manifestations was investigated in 176 patients with rheumatoid arthritis who had obtained, in a prospective study, a good clinical response to methotrexate (10 mg/week) taken for 33 months (range 4-68).Results: Before taking methotrexate, 44 patients (25.1%) had extra-articular manifestations: nodules (n = 40) and vasculitis (n = 9). With methotrexate, nodulosis and vasculitis were stable in 31 cases, improved in 3 and worsened in 10 (23%). Among the 132 patients without extra-articular manifestations before methotrexate therapy, 15 (11%) developed accelerated nodulosis preferentially located on the fingers, 7 had a vasculitis and 3 a pericarditis during methotrexate therapy. Extra-articular manifestations occurred between 1 and 24 months of initiating methotrexate therapy. Rheumatoid factor was positive in 88% of the patients with extra-articular manifestations. No relationship was noted between extra-articular manifestations and HLA type or antinuclear antibodies. In 3 out of 4 patients who developed accelerated nodulosis while taking methotrexate, the addition of hydroxychloroquine (400 mg/day) resulted in a significant reduction in the number and size of the nodules within 3 to 10 months after starting combined therapy.Conclusion: These data suggest that methotrexate is not effective in the treatment of extra-articular manifestations in rheumatoid arthritis and that nodulosis may occur in about 11% of patients taking methotrexate therapy for rheumatoid arthritis. The combination of hydroxychloroquine and methotrexate may have a beneficial effect on nodulosis that needs to be evaluated.application/pdfISSN: 1165-0478https://repository.urosario.edu.co/handle/10336/27919engNational Center for Biotechnology Information160No. 3153The European journal of medicineVol. 2The European journal of medicine, ISSN: 1165-0478, Vol.2, No.3 (1993); pp. 153-160https://pubmed.ncbi.nlm.nih.gov/8261056/Bloqueado (Texto referencial)http://purl.org/coar/access_right/c_14cbThe European journal of medicineinstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURMethotrexateVasculitisAccelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritisNódulosis acelerada y manifestaciones sistémicas durante el tratamiento con metotrexato para la artritis reumatoidearticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Anaya, Juan-ManuelSany, J.Combe, BDidry, CGutiérrez Peláez, Miguel10336/27919oai:repository.urosario.edu.co:10336/279192021-08-10 16:53:37.896https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |
dc.title.spa.fl_str_mv |
Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis |
dc.title.TranslatedTitle.spa.fl_str_mv |
Nódulosis acelerada y manifestaciones sistémicas durante el tratamiento con metotrexato para la artritis reumatoide |
title |
Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis |
spellingShingle |
Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis Methotrexate Vasculitis |
title_short |
Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis |
title_full |
Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis |
title_fullStr |
Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis |
title_full_unstemmed |
Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis |
title_sort |
Accelerated nodulosis and systemic manifestations during methotrexate therapy for rheumatoid arthritis |
dc.subject.keyword.spa.fl_str_mv |
Methotrexate Vasculitis |
topic |
Methotrexate Vasculitis |
description |
Objectives: Methotrexate is successfully used in the treatment of arthritis but little is known about its effects on extra-articular manifestations of rheumatoid arthritis. We focused this work on the incidence and clinical course of extra-articular manifestations during long-term treatment with methotrexate.Methods: The effect of methotrexate on extra-articular manifestations was investigated in 176 patients with rheumatoid arthritis who had obtained, in a prospective study, a good clinical response to methotrexate (10 mg/week) taken for 33 months (range 4-68).Results: Before taking methotrexate, 44 patients (25.1%) had extra-articular manifestations: nodules (n = 40) and vasculitis (n = 9). With methotrexate, nodulosis and vasculitis were stable in 31 cases, improved in 3 and worsened in 10 (23%). Among the 132 patients without extra-articular manifestations before methotrexate therapy, 15 (11%) developed accelerated nodulosis preferentially located on the fingers, 7 had a vasculitis and 3 a pericarditis during methotrexate therapy. Extra-articular manifestations occurred between 1 and 24 months of initiating methotrexate therapy. Rheumatoid factor was positive in 88% of the patients with extra-articular manifestations. No relationship was noted between extra-articular manifestations and HLA type or antinuclear antibodies. In 3 out of 4 patients who developed accelerated nodulosis while taking methotrexate, the addition of hydroxychloroquine (400 mg/day) resulted in a significant reduction in the number and size of the nodules within 3 to 10 months after starting combined therapy.Conclusion: These data suggest that methotrexate is not effective in the treatment of extra-articular manifestations in rheumatoid arthritis and that nodulosis may occur in about 11% of patients taking methotrexate therapy for rheumatoid arthritis. The combination of hydroxychloroquine and methotrexate may have a beneficial effect on nodulosis that needs to be evaluated. |
publishDate |
1993 |
dc.date.created.spa.fl_str_mv |
1993 |
dc.date.accessioned.none.fl_str_mv |
2020-08-19T14:44:38Z |
dc.date.available.none.fl_str_mv |
2020-08-19T14:44:38Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.issn.none.fl_str_mv |
ISSN: 1165-0478 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/27919 |
identifier_str_mv |
ISSN: 1165-0478 |
url |
https://repository.urosario.edu.co/handle/10336/27919 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
160 |
dc.relation.citationIssue.none.fl_str_mv |
No. 3 |
dc.relation.citationStartPage.none.fl_str_mv |
153 |
dc.relation.citationTitle.none.fl_str_mv |
The European journal of medicine |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 2 |
dc.relation.ispartof.spa.fl_str_mv |
The European journal of medicine, ISSN: 1165-0478, Vol.2, No.3 (1993); pp. 153-160 |
dc.relation.uri.spa.fl_str_mv |
https://pubmed.ncbi.nlm.nih.gov/8261056/ |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_14cb |
dc.rights.acceso.spa.fl_str_mv |
Bloqueado (Texto referencial) |
rights_invalid_str_mv |
Bloqueado (Texto referencial) http://purl.org/coar/access_right/c_14cb |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
National Center for Biotechnology Information |
dc.source.spa.fl_str_mv |
The European journal of medicine |
institution |
Universidad del Rosario |
dc.source.instname.none.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.none.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1814167633581309952 |